ANIFROLUMAB

Course overview

ANIFROLUMAB IS A NOVEL INVESTIGATIONAL AGENT USED IN THE MANAGEMENT AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). IT IS A FULLY HUMANIZED IGG1K MONOCLONAL ANTIBODY THAT INHIBITS CELLULAR SIGNALING TRANSMITTED BY THE TYPE 1 INTERFERON RECEPTOR (IFNAR1) UPON ACTIVATION. THIS ACTIVITY WILL HIGHLIGHT THE INDICATIONS, MECHANISM OF ACTION, PHARMACOKINETICS, ADVERSE EVENTS, AND CONTRAINDICATIONS OF ANIFROLUMAB. THIS ACTIVITY WILL CONCLUDE IN DESCRIBING ANIFROLUMAB’S ROLE IN THERAPY AND THE CLINICAL APPROACH INTERPROFESSIONAL TEAMS CAN TAKE IN EFFECTIVELY TREATING SLE.